# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k091657   
B. Purpose for Submission: Device modification to k052133 The modifications are: a. Double the highest calibrator level from $1 6 0 0 \ \mathrm { U / m L }$ to $3 2 0 0 \mathrm { U / m L }$ b. Replace strips of twelve wells with a 96-well microtiter plate   
C. Measurand: Anti-cyclic citrullinated peptide (CCP) IgG autoantibodies   
D. Type of Test: Qualitative and Semi-quantitative ELISA   
E. Applicant: Euro-Dagnostica AB   
F. Proprietary and Established Names: Immunoscan CCP Plus $^ \mathrm { \textregistered }$   
G. Regulatory Information: 1. Regulation section: 21 CFR $\$ 866.5775$ , Rheumatoid factor immunological test system 2. Classification: Class II 3. Product code: NHX, Antibodies, Anti-Cyclic Citrullinated Peptide (CCP) 4. Panel: Immunology (82)   
H. Intended Use: 1. Intended use(s): The Immunoscan CCP Plus $^ \mathrm { \textregistered }$ test kit is an enzyme-linked immunosorbent assa (ELISA) for qualitative and semi-quantitative determination of IgG antibodies cyclic citrullinated peptides (CCP) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used an aid in the diagnosis of Rheumatoid Arthritis (RA), in conjunction with othe laboratory and clinical findings. The analysis should be performed by trained laboratory professionals. “For in vitro diagnostic use”. 2. Indication(s) for use: Same as intended use. 3. Special conditions for use statement(s): For prescription use only. 4. Special instrument requirements: Microplate reader capable of measuring OD at $4 5 0 ~ \mathrm { \ n m }$ Microplate washer $3 0 0 \mu \mathrm { L }$ volume).

I. Device Description: Each device contains the following ready to use reagents: 1 sealed (96 wells) CCP peptide-coated microtiter plate; 5 vials containing calibrators (25, 50, 200, 800, 3200 $\mathrm { U } / \mathrm { m l } )$ ; reference, positive and negative controls (human serum in diluent); conjugate solution (peroxidase conjugated to anti human IgG antibodies); substrate solution $\mathrm { T M B } ( 3 , 3 ^ { \prime } , 5 , 5 ^ { \prime }$ -tetramethylbenzidin); dilution buffer; stop solution $0 . 5 { \mathrm { M } }$ sulfuric acid); wash buffer $2 0 \mathbf { x }$ concentrated.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Immunoscan RA anti-CCP Test Kit   
2. Predicate 510(k) number(s): k052133   
3. Comparison with predicate:

Similarities   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Modified Device Immunoscan CCPlus®</td><td rowspan=1 colspan=1>Predicate DeviceImmunoscan RAanti-CCP</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>The Immunoscan CCPlus® test kit is anenzyme-linked immunosorbent assay(ELISA) for qualitative and semi-quantitative determination of IgGantibodies to CCP in human sera. Theassay is used to detect antibodies in asingle serum specimen. The results of theassay are to be used as an aid to thediagnosis of RA, in conjunction with otherlaboratory and clinical findings. Theanalysis should be performed by trainedlaboratory professionals. &quot;For in vitrodiagnostic use&quot;.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Type of test</td><td rowspan=1 colspan=1>Qualitative and semi-quantitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analyte measured</td><td rowspan=1 colspan=1>Anti-CCP</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Coated antigen</td><td rowspan=1 colspan=1>Synthetic CCP</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Horse radish peroxidase (HRP) labelledAnti-human IgG</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB (3, 3&#x27;, 5, 5&#x27;-tetramethylbenzidin)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Wavelength</td><td rowspan=1 colspan=1>450 nm</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Incubation time</td><td rowspan=1 colspan=1>60 min + 30 min + 30 min</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>≥25 U/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Samplepreparation</td><td rowspan=1 colspan=1>Dilute 1:50</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Microtiter plate</td><td rowspan=1 colspan=1>Material: PolystyreneSurface: MaxiSorp</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Reference control, Negative control Positivecontrol</td><td rowspan=1 colspan=1>Same</td></tr></table>

Differences   

<table><tr><td>Item</td><td>Modified Device 4 Immunoscan CCPlus</td><td>Predicate Device Immunoscan RA anti-CCP</td></tr><tr><td>Microtiter plate</td><td>96 individual wells plate</td><td>8 strips x 12 wells plate</td></tr><tr><td>Calibrators</td><td>25 U/mL, 50 U/mL, 200 U/mL, 800 U/mL, 3200 U/mL Note: The same material is used to produce the calibrator</td><td>25 U/mL, 50 U/mL, 200 U/mL, 800 U/mL, 1600 U/mL</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

None provided

# L. Test Principle:

The Immunoscan CCPlus $^ \mathrm { \textregistered }$ test kit is an enzyme-linked immunosorbent assay (ELISA) for detection and semi-quantitation of IgG antibodies to CCP in human sera. The test utilizes microtiter plate wells coated with citrullinated synthetic peptides (antigen). Diluted patient serum is applied to the wells and incubated. If specific antibodies are present, they will bind to the antigen in the wells. Unbound material is washed away and any bound antibody is detected by adding horse radish peroxidase (HRP) labelled anti-human IgG, followed by a second washing step then incubation with substrate. The presence of reacting antibodies will result in the development of colour, which is proportional to the quantity of bound antibody, and this is determined photometrically.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Intra-assay precision was determined by testing six different samples across the measuring range (two high eight times each). The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>High</td><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=2>Low</td></tr><tr><td rowspan=1 colspan=1>Mean (U/mL).</td><td rowspan=1 colspan=1>2672</td><td rowspan=1 colspan=1>2685</td><td rowspan=1 colspan=1>1150</td><td rowspan=1 colspan=1>239</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>S.D. (U/mL)</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1>205</td><td rowspan=1 colspan=1>55.3</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>% C.V.</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>1.9</td></tr></table>

Two additional samples were run (8 replicates each) – a weak positive sample and one just below the cut off of $2 5 \mathrm { ~ U } / \mathrm { m l }$ . The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>&lt; 25 U/ml</td><td rowspan=1 colspan=1>Weak positive</td></tr><tr><td rowspan=1 colspan=1>Mean (U/mL)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>S.D. (U/mL)</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.5</td></tr><tr><td rowspan=1 colspan=1>% C.V.</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>3.6</td></tr></table>

Inter-assay precision/reproducibility was determined by testing six samples eight times each. Results were obtained for three different runs:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>High</td><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=2>Low</td></tr><tr><td rowspan=1 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=1>2696</td><td rowspan=1 colspan=1>2600</td><td rowspan=1 colspan=1>1168</td><td rowspan=1 colspan=1>242</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>S.D. (U/mL)</td><td rowspan=1 colspan=1>328</td><td rowspan=1 colspan=1>299</td><td rowspan=1 colspan=1>101.7</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>% C.V.</td><td rowspan=1 colspan=1>12.2</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>4.9</td></tr></table>

Two additional samples were run in 3 plates and 8 replicates each– a weak positive sample and one just below the cut off of $2 5 \mathrm { ~ U } / \mathrm { m l }$ . The results are summarized below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>&lt; 25 U/ml</td><td rowspan=1 colspan=1>Weak positive</td></tr><tr><td rowspan=1 colspan=1>Mean (U/mL)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>S.D. (U/mL)</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.5</td></tr><tr><td rowspan=1 colspan=1>% C.V.</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.8</td></tr></table>

Lot to lot variation was determined by testing six different samples eight replicates each. Results were obtained for three different lots. The results are summarized below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>High</td><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=2>Low</td></tr><tr><td rowspan=1 colspan=1>Mean (U/mL)</td><td rowspan=1 colspan=1>2896</td><td rowspan=1 colspan=1>2870</td><td rowspan=1 colspan=1>1530</td><td rowspan=1 colspan=1>259</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>S.D. (U/mL)</td><td rowspan=1 colspan=1>405</td><td rowspan=1 colspan=1>335</td><td rowspan=1 colspan=1>260.4</td><td rowspan=1 colspan=1>21.8</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>% C.V.</td><td rowspan=1 colspan=1>14.0</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>17.0</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>10.8</td></tr></table>

Reproducibility: The reproducibility of the qualitative protocol around the assay cut-off was determined by testing two samples eight times each on three different days $( \mathtt { n } = 2 4 )$ ). All results were negative for the sample with 19 Units $/ \mathrm { m l }$ concentration and all results were positive for the sample with 28 Units/ml.

# b. Linearity/assay reportable range:

Dilution recovery of three high concentration samples was determined by testing five serial dilutions of each sample. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Dilutionof sample</td><td rowspan=1 colspan=1>ObservedMean conc(Units/mL)</td><td rowspan=1 colspan=1>ExpectedMean conc(Units/mL)</td><td rowspan=1 colspan=1>Dilution% recovery</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1/50 - 1/800</td><td rowspan=1 colspan=1>114-1506</td><td rowspan=1 colspan=1>94-1506</td><td rowspan=1 colspan=1>100-121</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1/50-1/800</td><td rowspan=1 colspan=1>63-921</td><td rowspan=1 colspan=1>58-921</td><td rowspan=1 colspan=1>100-112</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1/50 - 1/800</td><td rowspan=1 colspan=1>194 - 2962</td><td rowspan=1 colspan=1>185-2962</td><td rowspan=1 colspan=1>94 - 105</td></tr></table>

Four additional samples were tested with concentrations 164, 180, 321 and $3 9 5 \ \mathrm { U / m L }$ . The results are shown in the table below:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Dilutionof sample</td><td rowspan=1 colspan=1>ObservedMean conc(Units/ml)</td><td rowspan=1 colspan=1>ExpectedMean conc(Units/ml)</td><td rowspan=1 colspan=1>Dilution% recovery</td></tr><tr><td rowspan=1 colspan=1>MK-RA 039</td><td rowspan=1 colspan=1>1/50 - 1/1600</td><td rowspan=1 colspan=1>6.0 - 164</td><td rowspan=1 colspan=1>6.0 - 164</td><td rowspan=1 colspan=1>98 - 105</td></tr><tr><td rowspan=1 colspan=1>MK-RA 086</td><td rowspan=1 colspan=1>1/50−1/1600</td><td rowspan=1 colspan=1>6.8- 180</td><td rowspan=1 colspan=1>6.0 - 180</td><td rowspan=1 colspan=1>92-113</td></tr><tr><td rowspan=1 colspan=1>MK-RA 120</td><td rowspan=1 colspan=1>1/50-1/3200</td><td rowspan=1 colspan=1>6.2 - 321</td><td rowspan=1 colspan=1>6.0 - 321</td><td rowspan=1 colspan=1>99 - 110</td></tr><tr><td rowspan=1 colspan=1>MK-RA 169</td><td rowspan=1 colspan=1>1/50 - 1/3200</td><td rowspan=1 colspan=1>7.8 - 395</td><td rowspan=1 colspan=1>6.5 - 395</td><td rowspan=1 colspan=1>98 - 120</td></tr></table>

The measuring assay range is $2 5 { \cdot } 2 9 6 2 \ \mathrm { U } / \mathrm { m L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods): There is no widely accepted reference standard for anti-CCP. The calibrators and controls (positive and negative) are prepared in-house and arbitrary units are assigned during the development process.

d. Detection limit:

The limit of blank (LoB) was determined by running the zero standard 14 times on three different lots. The LoB of $1 . 6 \ : \mathrm { U / m L }$ was calculated by finding the mean plus two standard deviations.

e. Analytical specificity:

Interference Study/Endogenous compounds: Three low positive samples were spiked with bilirubin at $0 . 2 ~ \mathrm { m g / m L }$ , hemoglobin at $4 0 0 \mathrm { m g / d L }$ , lipid at 15 $\mathrm { m g / m L }$ and rheumatoid factor at $2 0 0 \ : \mathrm { I U / m L }$ . The data indicates that the assayed concentrations do not interfere with the anti-CCP results. Please refer to the predicate (k052133) for more details on the studies conducted for the device.

Assay cut-off:

The cut-off of $2 5 \mathrm { \ : U / m L }$ was established in the predicate assay. The proposed modification did not alter the cut-off.

Semi-Quantitative protocol:

Samples with results $< 2 5 \ \mathrm { U / m L }$ are defined as negative.

Samples $\ge 2 5 ~ \mathrm { U / m L }$ are defined as positive.

Euro-Diagnostica recommends the following cut-off:

Absorbance ratio Result Interpretation $\begin{array} { l } { < 0 . 9 5 } \\ { \geq 0 . 9 5 \mathrm { t o } \leq 1 . 0 } \\ { > 1 . 0 } \end{array}$ Negative Borderline - recommend repeat testing Positive

Users should calculate a cut-off between positive and negative samples that is specific to their patient populations.

2. Comparison studies:

a. Method comparison with predicate device: A study was done to evaluate the percent agreement between the Immunoscan CCPlus $^ \mathrm { \textregistered }$ kit compared to Immunoscan RA anti-CCP. A total of 659 frozen retrospective sera were assayed (399 samples were from RA patients and 260 samples were from apparently healthy blood donors). The following table summarizes the results:

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>Immunoscan RA anti-CCP</td></tr><tr><td rowspan=4 colspan=1>ImmunoscanCCPlus® Kit</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>275</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>280</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>346</td><td rowspan=1 colspan=1>348</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>277</td><td rowspan=1 colspan=1>351</td><td rowspan=1 colspan=1>628</td></tr></table>

Positive Percent Agreement: $2 7 5 / 2 7 7 = 9 9 . 3 \%$ $( 9 5 \% \mathrm { C I } = 9 7 . 4 - 9 9 . 9 )$ Negative Percent Agreement: $3 4 6 / 3 5 1 = 9 8 . 6 \%$ $( 9 5 \% \mathrm { C I } = 9 6 . 7 - 9 9 . 5 )$ Overall Percent Agreement: $6 2 1 / 6 2 8 = 9 8 . 9 \%$ $( 9 5 \% \mathrm { C I } = 9 7 . 7 - 9 9 . 6 )$

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity:

A total of 1180 frozen retrospective sera with clinical characterization were assayed. The following table summarizes the results:

<table><tr><td></td><td>n</td><td>negative</td><td>positive</td><td>Sensitivity (95% CI)</td></tr><tr><td>Patients with</td><td></td><td></td><td></td><td>77.4%</td></tr><tr><td>clinically defined RA</td><td>399</td><td>90</td><td>309</td><td>(73.1%- 81.5%)</td></tr></table>

b. Clinical specificity:

For the clinical specificity study, non-RA diseased patients and asymptomatic individuals (healthy blood donors) were used. The results are summarized below:

Blood donors $2 5 7 / 2 6 0 = 9 8 . 8 \%$ $9 5 \% \mathrm { C I } = 9 6 . 7 - 9 9 . 8 \%$ WG $1 8 / 2 0 = 9 0 . 0 \%$ $9 5 \% \mathrm { C I } = 6 8 . 3 - 9 8 . 8 \%$ MP $2 0 / 2 0 = 1 0 0 \%$ $9 5 \% \mathrm { C I } = 8 3 . 2 \textrm { - } 1 0 0 \%$ SLE $6 4 / 6 6 = 9 7 . 0 \%$ $9 5 \% \mathrm { C I } = 8 9 . 5 - 9 9 . 6 \%$

Sjogren’s 13/13 = 100 % $9 5 \% \mathrm { C I } = 7 5 . 3 \cdot 1 0 0 \%$ IBD 95/98 = 96.9% $9 5 \% \mathrm { C I } = 9 1 . 3 - 9 9 . 4 \%$ Osteoarthritis 21/21 = 100% $9 5 \% \mathrm { C I } = 8 3 . 9 \cdot 1 0 0 \%$ Thyroiditis 20/20 = 100% $9 5 \% \mathrm { C I } = 8 3 . 2 \textrm { - } 1 0 0 \%$ Infectious Disease 85/86 = 98.8% $9 5 \% \mathrm { C I } = 9 3 . 7 \cdot 1 0 0 \%$ Scleroderma 16/17 = 94.1% $9 5 \% \mathrm { C I } = 7 1 . 3 - 9 9 . 8 \%$ Multiple Sclerosis $2 0 / 2 0 = 1 0 0 \%$ $9 5 \% \mathrm { C I } = 8 3 . 2 \textrm { - } 1 0 0 \%$ IDDM $2 0 / 2 0 = 1 0 0 \%$ $9 5 \% \mathrm { C I } = 8 3 . 2 \textrm { - } 1 0 0 \%$ PM/DM $2 0 / 2 0 = 1 0 0 \%$ $9 5 \% \mathrm { C I } = 8 3 . 2 \textrm { - } 1 0 0 \%$ MCTD $1 9 / 2 0 = 9 5 . 0 \%$ $9 5 \% \mathrm { C I } = 7 5 . 1 \cdot 9 9 . 9 \%$ Suspected autoimmune disease (samples undefined) $7 8 / 8 0 = 9 7 . 5 \ \%$ $9 5 \% \mathrm { C I } = 9 1 . 3 \cdot 9 9 . 7 \%$ Overall specificity $= 7 6 6 / 7 8 1 { = } 9 8 . 1 \%$ $9 5 \% \% \mathrm { C I } = 9 6 . 9 - 9 8 . 9 \%$ c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Same as assay cut-off.   
5. Expected values/Reference range: Expected values in the normal population should be negative.

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.